Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.59 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
| ▸ | TDP2 | O95551 | 1/20 | 0.48 |
| ▸ | NSD2 | O96028 | 2/20 | 0.46 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.43 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.42 |
| ▸ | PGR | P06401 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17027197 | 0.88 | KIF11 (0.67) | KIF11CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL30016963 | 0.88 | KIF11 (0.67) | KIF11CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL4596025 | 0.86 | KIF11 (0.47) | KIF11CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL4595242 | 0.86 | KIF11 (0.64) | KIF11CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL19188092 | 0.81 | MMP12 (0.62) | CYP11B1CYP11B2PDE3BPDE3ANSD2 | |
| SCHEMBL3110112 | 0.79 | MMP12 (0.59) | KIF11MCL1POLBMMP12TRPV1 | |
| SCHEMBL4596644 | 0.79 | KIF11 (0.70) | KIF11CYP11B1CYP11B2PDE3BPDE3A | |
| SCHEMBL4596129 | 0.79 | KIF11 (0.42) | KIF11CYP11B1CYP11B2TDP2NR3C2 | |
| SCHEMBL14154359 | 0.78 | KIF11 (0.47) | KIF11CYP11B1CYP11B2TDP2 | |
| SCHEMBL4596423 | 0.78 | KIF11 (0.47) | KIF11CYP11B1CYP11B2TDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | claimed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| US-20080176830-A1 | Compounds, Compositions, and Methods | ADAMS NICHOLAS D | 2008-07-24 | — | — | US | disclosed |
| EP-1874753-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006113432-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176830-A1 | Compounds, Compositions, and Methods | ALPP, PCNA, MKI67 | KIF11 562/4885CYP11B1 780/4885CYP11B2 1046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.